The Dose Is Part of the Drug: Why Molecule-First Discovery Stops Too Early

Medicinal chemistry teaches us to look at a molecule as if it were the product: a structure, a potency value, a selectivity panel, perhaps an attractive set of ADME properties. But a patient never receives a molecular drawing. The patient receives a formulation, at a dose, on a schedule, under conditions that produce a changing concentration in plasma and tissues. That concentration may or may not reach the disease compartment. It may engage the intended target briefly, continuously, or not at all. The biological system may adapt between doses. Two patients given the same tablet can therefore experience meaningfully different drugs.

This is why molecule-first discovery often stops one abstraction too early. The true object being optimized is a molecule-formulation-dose-schedule-patient system.

A potent molecule can still be pharmacologically absent

One of the most useful translational frameworks in modern drug research is the three-pillar idea associated with Paul Morgan and colleagues: before expecting clinical efficacy, establish that the molecule reaches the site of action, binds the target there, and produces the intended functional pharmacology. The pillars sound obvious. In practice, discovery programs frequently demonstrate only a diluted version of them: plasma exposure instead of disease-tissue exposure, biochemical potency instead of target engagement in living systems, and a proximal biomarker instead of a response plausibly connected to patient benefit.

• Exposure: Is enough unbound drug present in the relevant tissue for long enough?
• Target engagement: Does the drug occupy or modulate the intended target at that exposure?
• Functional response: Does that engagement move the disease mechanism in the predicted direction and magnitude?

A failure at any one layer can make an excellent molecule look like a failed biological hypothesis. That distinction matters because the next decision is completely different. Wrong target biology suggests stopping the programme. Inadequate tissue exposure suggests changing chemistry, formulation, route, dose, or schedule. Without the translation chain, those causes are easily confused.

Plasma concentration is a map, not the destination

Drug development relies heavily on plasma PK because blood is accessible, standardized, and measurable over time. But plasma is often only a surrogate for the biophase where pharmacology occurs. Brain penetration, intracellular accumulation, lysosomal trapping, tumour perfusion, transporter activity, protein binding, active metabolites, and local pH can all separate measured plasma concentration from effective concentration at the target.

The important question is not simply whether exposure exceeds an in-vitro IC50. It is whether the unbound concentration at the relevant site, across the dosing interval, is consistent with the degree and duration of target modulation required by the disease mechanism. That is a PBPK and PK/PD question as much as a chemistry question.

Duration can matter more than peak potency

Different mechanisms encode different time requirements. A reversible inhibitor may need sustained coverage. A covalent inhibitor may preserve target suppression after plasma drug has fallen. An immune agonist may benefit from pulses rather than continuous stimulation. A cell-cycle mechanism may depend on exposing cells during a specific biological window. Receptor internalization, feedback signalling, protein turnover, tolerance, and pathway rebound can all make the same daily exposure behave differently when delivered as one large dose, divided doses, an infusion, or an intermittent schedule.

The question is not only “Does this molecule work?” It is “What pattern of exposure makes this mechanism work without destroying the safety margin?”

This is one reason dose optimization cannot be postponed until the molecule is effectively finished. If the desired pharmacology requires an exposure profile that the molecule cannot safely deliver, the problem belongs in discovery. The chemistry team may need to alter half-life, permeability, tissue distribution, residence time, or active-metabolite formation. Regimen design and molecular design are coupled.

Maximum tolerated dose is not the same as optimal dose

Classical cytotoxic oncology often escalated toward the maximum tolerated dose because more exposure was expected to kill more rapidly dividing cells. That logic does not automatically transfer to targeted therapies, degraders, immune modulators, or pathway inhibitors. Efficacy may plateau once target engagement is saturated, while toxicity continues to increase. The FDA's Project Optimus reflects this broader shift: dose selection should integrate efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics, and exposure-response evidence rather than treating the highest tolerable dose as the default answer.

The deeper lesson reaches beyond oncology. A dose is a decision about benefit-risk, not merely a conversion from milligrams to concentration. The preferred regimen may differ by organ function, genotype, age, interacting medicines, disease severity, body composition, or molecular subtype. Population variability is part of the drug's real operating environment.

Discovery should begin with a target product exposure profile

Teams routinely write a target product profile describing the intended indication, population, efficacy, safety, and commercial properties. An equally useful companion is a target product exposure profile:

• Which tissue and cell population must be reached?
• What target-engagement threshold is associated with biological response?
• Must engagement be continuous, pulsatile, or transient?
• How quickly does the target or pathway recover?
• Which exposure metric best predicts efficacy: Cmax, trough, average concentration, time above threshold, or cumulative exposure?
• Which exposure metric predicts toxicity, and in which organ?
• How much interpatient variability can the therapeutic window tolerate?

These questions convert a vague ambition -- “find a potent molecule” -- into a translational engineering specification. They also reveal early when the desired product may be physically or biologically implausible.

The molecule is only the first model

A modern discovery programme should maintain a connected chain from target and disease mechanism to candidate properties, tissue exposure, target engagement, biological response, safety margin, patient subgroup, and clinical outcome. Each link carries uncertainty. Each experiment should update one or more links. A programme becomes more intelligent not when it produces more predictions, but when it can explain which link is currently weakest and which next experiment would reduce decision uncertainty most.

That is the practical meaning of model-informed discovery. The molecule matters enormously. But it becomes a medicine only when a feasible regimen produces the right exposure, in the right place, for the right duration, in patients whose biology can respond.